scispace - formally typeset
E

Eduard Maron

Researcher at Imperial College London

Publications -  83
Citations -  2729

Eduard Maron is an academic researcher from Imperial College London. The author has contributed to research in topics: Anxiety & Panic disorder. The author has an hindex of 29, co-authored 80 publications receiving 2364 citations. Previous affiliations of Eduard Maron include Tartu University Hospital & Centre for Mental Health.

Papers
More filters
Journal ArticleDOI

Variation in tryptophan hydroxylase-2 gene is not associated to male completed suicide in Estonian population.

TL;DR: The finding does not support the hypothesis of TPH2 being a susceptibility factor for completed suicide in males of Estonian origin and any associations between 14 single nucleotide polymorphisms and completed suicide were revealed.
Journal ArticleDOI

Whole-genome expression analysis reveals genes associated with treatment response to escitalopram in major depression

TL;DR: The results of this study support that exploration of peripheral gene expression is a useful tool in the further identification of novel genetic biomarkers for antidepressant treatment response.
Journal ArticleDOI

Precision psychiatry in clinical practice.

TL;DR: Only genetic variants in cytochrome enzymes are endorsed by prescribing guidelines, but in the future polygenic predictors of treatment outcomes may be translated into the clinic and represented an important step towards precision psychiatry.
Journal Article

The role of IL-2 and soluble IL-2R in depression and antidepressant response.

TL;DR: There has been no consistent pattern in the associations observed between cytokine concentration, or changes thereof, and clinical indices of major depression and one intriguing question is whether pretreatment levels of immune system markers, such as IL-2R alpha, can be used to predict responses to antidepressant treatment.
Journal ArticleDOI

Thyroid autoimmunity and treatment response to escitalopram in major depression.

TL;DR: Thyroid autoimmunity might be a factor predicting treatment response to antidepressants in depressive patients, and the last group showed a trend for a higher prevalence of anti-TPO compared with responders.